Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FM101 phase 2a study in adults with NAFLD or NASH
2020-005187-63Phase 2Terminated
- Sponsor
- Future Medicine
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of FM101 in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Future Medicine. Primary endpoint: Treatment-emergent adverse events. Started Feb 2021; status: terminated.
02
Drugs
FM101
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2020-005187-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005187-63.